INTENTLY FOCUSED

By David SchoonmakerINTENTLY FOCUSEDDemonstrating the power of combining scientific curiosity with product safety. STEVE PETTEWAYJASON VARNEY | VARNEYPHOTO.COM Stephen R. Petteway, Jr. regularly asks himself, "If I were a patient, what would I want to see in my products?" Unmet patient needs are his primary motivator, and he encourages the same attitude among the roughly 330 scientists, engineers, and technicians he directs at Talecris Biotherapeutics'

| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

Stephen R. Petteway, Jr. regularly asks himself, "If I were a patient, what would I want to see in my products?" Unmet patient needs are his primary motivator, and he encourages the same attitude among the roughly 330 scientists, engineers, and technicians he directs at Talecris Biotherapeutics' plant in Clayton, NC, as well as its research and testing laboratories in Raleigh and Research Triangle Park. With more than 25 years in the pharmaceutical business, the last 11 of them with Bayer and Talecris, he brings a wealth of knowledge and experience to developing protein therapies, and moving them out of the lab and safely into the clinic as quickly as possible.

Known in the scientific community for pioneering work on HIV and pathogen safety in blood plasma-based medicines, Petteway is the senior vice president of R&D at Talecris and has been chairperson of the Plasma Protein Therapies Association's plasma-safety steering ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • David Schoonmaker

    This person does not yet have a bio.

Published In

Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Photo of a researcher overseeing large scale production processes in a laboratory.

Scaling Lentiviral Vector Manufacturing for Optimal Productivity

Thermo Fisher Logo
Collage-style urban graphic of wastewater surveillance and treatment

Putting Pathogens to the Test with Wastewater Surveillance

An illustration of an mRNA molecule in front of a multicolored background.

Generating High-Quality mRNA for In Vivo Delivery with lipid nanoparticles

Thermo Fisher Logo
Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide